Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefaclor
Drug ID BADD_D00378
Description Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Indications and Usage For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.
Marketing Status approved
ATC Code J01DC04
DrugBank ID DB00833
KEGG ID D00256; D02352
MeSH ID D002433
PubChem ID 51039
TTD Drug ID D0PW7C
NDC Product Code 0093-1087; 23594-250; 23594-375; 23594-125; 61442-171; 61442-172; 81948-6250
UNII 69K7K19H4L
Synonyms Cefaclor | Cefaclor Anhydrous | Keclor | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))- | S-6472 | S 6472 | S6472 | Ceclor | Cefaclor Monohydrate | Lilly 99638
Chemical Information
Molecular Formula C15H14ClN3O4S
CAS Registry Number 53994-73-3
SMILES C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint swelling15.01.02.004--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.001--Not Available
Lip swelling10.01.05.005; 07.05.04.005; 23.04.01.007--Not Available
Loss of consciousness17.02.04.0040.000073%Not Available
Lung disorder22.02.07.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphocyte count decreased13.01.06.006--
Lymphocytosis01.02.01.003--Not Available
Malaise08.01.01.0030.000146%
Menstrual disorder21.01.01.004--Not Available
Mouth ulceration07.05.06.004--Not Available
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nephropathy20.05.03.001--Not Available
Nephropathy toxic12.03.01.010; 20.05.03.002--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neutropenia01.02.03.004--Not Available
Nightmare19.02.03.003--Not Available
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Osteoarthritis15.01.04.001--Not Available
Otitis media11.01.05.004; 04.05.01.001--
Pain08.01.08.004--
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene